
Adam C Winters

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2658073/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 126-135.	2.4	32
2	Liver Cancer Has a Distinctive Profile in Black Patients: Current Screening Guidelines May Be Inadequate. Hepatology Communications, 2022, 6, 8-11.	2.0	8
3	Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group. Clinical Gastroenterology and Hepatology, 2021. 19. 2407-2416.e8.	2.4	52
4	Joining the Fight: Enhancing Alcohol Treatment Education in Hepatology. Clinical Liver Disease, 2021, 18, 225-229.	1.0	7
5	A Telephone and Mail Outreach Program Successfully Increases Uptake of Hepatocellular Carcinoma Surveillance. Hepatology Communications, 2020, 4, 825-833.	2.0	11
6	Acute Liver Failure During Pregnancy: Happy to Recover from Hep E. Digestive Diseases and Sciences, 2020, 65, 2515-2517.	1.1	0
7	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2952-2961.e8.	2.4	48
8	Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach. Clinics in Liver Disease, 2019, 23, 607-623.	1.0	20
9	A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post–liver transplant patient. Clinical Transplantation, 2019, 33, e13700.	0.8	22
10	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflammatory Bowel Diseases, 2019, 25, 1854-1861.	0.9	11
11	The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. Case Reports in Hematology, 2019, 2019, 1-3.	0.3	7
12	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2497-2505.e1.	2.4	44
13	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1533-1540.e2.	2.4	60
14	Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis. Hepatology, 2018, 67, 1150-1157.	3.6	6
15	At Diagnosis of Hepatocellular Carcinoma, African Americans With Hepatitis C Have Better Liver Function Than Other Patients. Clinical Liver Disease, 2018, 12, 109-112.	1.0	6
16	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology, 2018, 113, 1345.	0.2	119
17	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn'sÂDisease. Gastroenterology, 2018, 155, 687-695.e10.	0.6	93